CTNM
Contineum Therapeutics, Inc.
Next earnings Aug 3, 2026 · consensus $-0.49 EPS
Last earnings -1.0% on 2026-05-05
$14.19
▲ +6.21%$14.19▲ +245.26%
over 1Y
L $3.77EODHDH $16.00
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+6.2%
1W+6.2%
1M+5.6%
3M+6.4%
YTD+24.6%
1Y+245.3%
Sell
Conviction
Horizon
Medium (3–12mo)
Street · 13 analysts
Strong Buy
Conservative balance sheet (liabilities/equity 0.06x); but revenue fell -100.0% YoY.
Revenue (FY2024) $0.00 · FY2024
Contineum Therapeutics, Inc. shows $0.00 in FY2024 revenue (-100.0% YoY), and -23.0% ROE.
Financials · annual, by fiscal year
| Line item | FY23 | FY24 | FY25 |
|---|---|---|---|
| Revenue | $50.0M | $0.00 | — |
| Gross profit | — | — | — |
| Operating income | $16.1M | -$50.9M | -$68.1M |
| Net income | $22.7M | -$42.3M | -$60.0M |
| Diluted EPS | $0.08 | -$2.18 | -$2.17 |
| Net margin | 45.4% | — | — |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$292M
EV / EBITDA—
EV / Sales—
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-16.3%
FCF yield-15.1%
Quality & risk
ROIC (est.)-20.6%
Free cash flow-$55.5M
Total debt—
Net cash$75.6M
Altman Z-Score13.48 safe
Piotroski F-Score2/6
Capital returns
Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsSome governance/structural items recently, but no outright red flags.
Recent filings
all on EDGAR ↗4Period ending 2026-06-262026-06-26open ↗4Period ending 2026-06-262026-06-26open ↗4Period ending 2026-06-262026-06-26open ↗4Period ending 2026-06-262026-06-26open ↗4Period ending 2026-06-262026-06-26open ↗4Period ending 2026-06-262026-06-26open ↗4Period ending 2026-06-262026-06-26open ↗8-KPeriod ending 2026-06-262026-06-26open ↗4Period ending 2026-06-012026-06-01open ↗144Filing2026-06-01open ↗SCHEDULE 13G/AFiling2026-05-15open ↗SCHEDULE 13GFiling2026-05-15open ↗
Frequently asked
- Is Contineum Therapeutics, Inc. (CTNM) a buy?
- CTNM currently carries a Sell rating with 3/5 conviction, derived from its latest SEC filings. Conservative balance sheet (liabilities/equity 0.06x); but revenue fell -100.0% YoY.
- What is Contineum Therapeutics, Inc.'s quality score?
- CTNM scores 36.179487179487175/100 (grade F) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001855175, latest 10-Q filed 2026-05-05) · EODHD · as of 6/26/2026, 6:57:57 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.